Golestan University of Medical Sciences Repository

Effect of oral genistein administration in early and late phases of allergic encephalomyelitis

Razeghi Jahromi, S. and Arrefhosseini, S.R. and Ghaemi, A. and Alizadeh, A. and Sabetghadam, F. and Togha, M. (2014) Effect of oral genistein administration in early and late phases of allergic encephalomyelitis. Iranian Journal of Basic Medical Sciences, 17 (7). pp. 509-515. ISSN 20083866 (ISSN)

[img]
Preview
PDF - Published Version
Download (1MB) | Preview

Abstract

Objective(s): Experimental allergic encephalomyelitis (EAE) is an autoimmune disease validated as animal model of multiple sclerosis (MS). Administration of genistein, a phytoestrogenic component of soy, to mice at the onset of EAE is known to attenuate the clinical signs of the disease. The potential effects of genistein on established EAE is less studied. In the current study, we aimed to compare the effects of genistein administration on EAE severity in early and late phases of the disease. Materials and Methods: The C57BL/6 mice were induced with EAE, using MOG 35-55 and gavaged with genistein (300 mg/kg) either after the appearance of the first clinical sign or 30 days post disease induction for ten days. 24 hr after the last gavage, mice were sacrificed. Brains and spleens were removed for assessing lymphocyte proliferation, cell cytotoxicity, and cytokine profile. Spinal cords were dissected to assess the amount of demyelination using Luxol fast blue/cresyl violet staining. Results: Administering mice with genistein, after the establishment of EAE, did not reverse the clinical signs of disease. However, treating with genistein at the onset of disease alleviated the clinical signs by reducing neuronal demyelination. Genistein suppressed the production of IFN-γ and enhanced IL-10 secretion in splenocyte and brain. Genistein also reduced IL-12 and TNF-α secretion in splenocytes, suppressed the proliferation of T-cells, and reduced the cell cytotoxicity. Conclusion: Genistein oral therapy might only reduce EAE severity if started in early phases of the disease.

Item Type: Article
Additional Information: Unmapped bibliographic data: LA - English [Field not mapped to EPrints] J2 - Iran. J. Basic Med. Sci. [Field not mapped to EPrints] AD - Multiple Sclerosis Research Center-Neuroscience Institute, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran [Field not mapped to EPrints] AD - Shefa Neuroscience Research Center, Tehran, Iran [Field not mapped to EPrints] AD - Department of Nutrition and Health, Tabriz University of Medical Sciences, Iran [Field not mapped to EPrints] AD - Department of Virology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran [Field not mapped to EPrints] AD - Department of Tissue Engineering, Tehran University of Medical Sciences, Tehran, Iran [Field not mapped to EPrints] AD - DVM, Ferdowsi University of Mashhad, Mashhad, Iran [Field not mapped to EPrints] AD - Department of Neurology, Iranian Center of Neurological Research-Neuroscience Institute, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran [Field not mapped to EPrints] DB - Scopus [Field not mapped to EPrints]
Uncontrolled Keywords: Encephalomyelitis (EAE), Experimental allergic, Genistein, Immunomodulation, Interferon-gamma, Multiple sclerosis, genistein, allergic encephalomyelitis, animal experiment, animal model, animal tissue, article, controlled study, cytotoxicity, demyelination, enzyme linked immunosorbent assay, female, histology, lymphocyte proliferation, mouse, nonhuman
Subjects: مقالات نمایه شده محققین دانشگاه در سایت ,Web of Science ,Scopus
موارد کلی
Divisions: معاونت تحقیقات و فناوری
Depositing User: GOUMS
Date Deposited: 18 Apr 2015 05:52
Last Modified: 09 May 2015 05:09
URI: http://eprints.goums.ac.ir/id/eprint/1721

Actions (login required)

View Item View Item